MXPA05004917A - Combinacion que comprende docetaxel y un inhibidor cdk. - Google Patents
Combinacion que comprende docetaxel y un inhibidor cdk.Info
- Publication number
- MXPA05004917A MXPA05004917A MXPA05004917A MXPA05004917A MXPA05004917A MX PA05004917 A MXPA05004917 A MX PA05004917A MX PA05004917 A MXPA05004917 A MX PA05004917A MX PA05004917 A MXPA05004917 A MX PA05004917A MX PA05004917 A MXPA05004917 A MX PA05004917A
- Authority
- MX
- Mexico
- Prior art keywords
- docetaxel
- cdk inhibitor
- combination
- prodrug
- derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
Un primer aspecto de la presente invencion se refiere a una combinacion que comprende docetaxel o un derivado o profarmaco del mismo, y un inhibidor CDK. Un segundo aspecto de la presente invencion se refiere a un producto farmaceutico que comprende docetaxel o un derivado o profarmaco del mismo y un inhibidor CDK en la forma de una preparacion combinada para utilizarse en terapias en forma simultanea, en secuencias o por separado. Un tercer aspecto de la presente invencion se refiere a un metodo para tratar un padecimiento proliferativo, en donde el metodo comprende administrar un sujeto en forma simultanea, en secuencias o por separado docetaxel, o un derivado o profarmaco del mismo y un inhibidor CDK.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0225872.1A GB0225872D0 (en) | 2002-11-06 | 2002-11-06 | Combination |
| GB0318813A GB0318813D0 (en) | 2003-08-11 | 2003-08-11 | Combination |
| PCT/GB2003/004780 WO2004041268A1 (en) | 2002-11-06 | 2003-11-05 | Combination comprising docetaxel and a cdk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05004917A true MXPA05004917A (es) | 2005-08-18 |
Family
ID=32313983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05004917A MXPA05004917A (es) | 2002-11-06 | 2003-11-05 | Combinacion que comprende docetaxel y un inhibidor cdk. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20050277656A1 (es) |
| EP (1) | EP1558242B1 (es) |
| JP (1) | JP4764165B2 (es) |
| AT (1) | ATE418333T1 (es) |
| AU (1) | AU2003276467A1 (es) |
| BR (1) | BR0316010A (es) |
| CA (1) | CA2502973A1 (es) |
| DE (1) | DE60325502D1 (es) |
| ES (1) | ES2318202T3 (es) |
| MX (1) | MXPA05004917A (es) |
| WO (1) | WO2004041268A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
| US20070287718A1 (en) * | 2003-11-06 | 2007-12-13 | Green Simon R | Methods for the Treatment of Multiple Myeloma Using Roscovitine |
| ES2390237T3 (es) * | 2006-02-10 | 2012-11-07 | Nerviano Medical Sciences S.R.L. | Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico |
| ES2500465T3 (es) * | 2006-10-06 | 2014-09-30 | Bavarian Nordic Inc. | Virus vaccinia Ankara modificado recombinante que codifica antígeno HER-2 en combinación con un taxano para uso en el tratamiento del cáncer |
| EP2178531A4 (en) * | 2007-07-02 | 2012-01-11 | Yu Ming | METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS |
| JP6286421B2 (ja) | 2012-05-15 | 2018-02-28 | サイクラセル リミテッド | サパシタビン及びセリシクリブの投与レジメン |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| US6235776B1 (en) * | 1998-11-12 | 2001-05-22 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| GB9904932D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy |
| AU2002228849A1 (en) * | 2000-12-08 | 2002-06-18 | Bristol-Myers Squibb Pharma Company | Semicarbazides and their uses as cyclin dependent kinase inhibitors |
| UY27220A1 (es) * | 2001-03-23 | 2002-09-30 | Aventis Pharma Sa | Combinación de un taxano con una quinasa ciclina-dependiente |
| US6949558B2 (en) * | 2001-11-07 | 2005-09-27 | Yale University | Enhancement of taxane-based chemotherapy by a CDK1 antagonist |
| EP1485168A1 (en) * | 2002-03-15 | 2004-12-15 | Cyclacel Limited | Combination of a cdk inhibitor and 5-fu for the treatment of cancer |
| AU2003276463A1 (en) * | 2002-11-06 | 2004-06-07 | Cyclacel Limited | Combination comprising a cdk inhibitor and cisplatin |
| EP1558289A1 (en) * | 2002-11-06 | 2005-08-03 | Cyclacel Limited | Pharmaceutical composition comprising a cdk inhibitor and gemcitabine |
| GB0225873D0 (en) * | 2002-11-06 | 2002-12-11 | Cyclacel Ltd | Combination |
-
2003
- 2003-11-05 AT AT03810527T patent/ATE418333T1/de not_active IP Right Cessation
- 2003-11-05 CA CA002502973A patent/CA2502973A1/en not_active Abandoned
- 2003-11-05 AU AU2003276467A patent/AU2003276467A1/en not_active Abandoned
- 2003-11-05 DE DE60325502T patent/DE60325502D1/de not_active Expired - Lifetime
- 2003-11-05 EP EP03810527A patent/EP1558242B1/en not_active Expired - Fee Related
- 2003-11-05 MX MXPA05004917A patent/MXPA05004917A/es unknown
- 2003-11-05 ES ES03810527T patent/ES2318202T3/es not_active Expired - Lifetime
- 2003-11-05 JP JP2005502134A patent/JP4764165B2/ja not_active Expired - Fee Related
- 2003-11-05 WO PCT/GB2003/004780 patent/WO2004041268A1/en active Application Filing
- 2003-11-05 BR BR0316010-6A patent/BR0316010A/pt not_active Application Discontinuation
-
2005
- 2005-05-03 US US11/122,331 patent/US20050277656A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050277656A1 (en) | 2005-12-15 |
| EP1558242B1 (en) | 2008-12-24 |
| DE60325502D1 (de) | 2009-02-05 |
| WO2004041268A1 (en) | 2004-05-21 |
| CA2502973A1 (en) | 2004-05-21 |
| EP1558242A1 (en) | 2005-08-03 |
| JP2006508186A (ja) | 2006-03-09 |
| ATE418333T1 (de) | 2009-01-15 |
| BR0316010A (pt) | 2005-09-13 |
| JP4764165B2 (ja) | 2011-08-31 |
| ES2318202T3 (es) | 2009-05-01 |
| AU2003276467A1 (en) | 2004-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05004919A (es) | Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina. | |
| WO2005058233A3 (en) | Methods for treatment of acute pancreatitis | |
| TW200505924A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| TW200612922A (en) | Inhibitors of hsp90 | |
| BRPI0507482A (pt) | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap | |
| TW200633700A (en) | Methods of using temozolomide formulation intrathecally in the treatment of cancers | |
| GB0328180D0 (en) | Combination | |
| AU2003205768A1 (en) | Methods and compositions for treating hyperproliferative conditions | |
| ATE523200T1 (de) | Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel | |
| WO2006124689A3 (en) | Combination therapy | |
| MXPA05004917A (es) | Combinacion que comprende docetaxel y un inhibidor cdk. | |
| MXPA04009012A (es) | Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer. | |
| WO2005081972A3 (en) | Maleiimide anti-tumor phosphatase inhibitors | |
| MXPA05004920A (es) | Combinacion que comprende un inhibidor cdk y cisplatin. | |
| TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
| MXPA04009396A (es) | Combinacion que comprende un inhibidor cdk y doxorubicina. | |
| BR0316029A (pt) | Combinação | |
| WO2007054725A3 (en) | Combination of a cdk-inhibitor and a hdac-inhibitor | |
| MXPA05009849A (es) | Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2. | |
| WO2007146375A3 (en) | Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer | |
| HRP20050281A2 (en) | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes | |
| TW200500073A (en) | Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof | |
| AU2003240842A1 (en) | Synergistic combination of an opioid analgesic and a nsaid |